Repligen Corporation
Repligen Corporation (Nasdaq: RGEN) develops and commercializes technologies and systems used to manufacture biological drugs, including monoclonal antibodies, recombinant proteins, RNA-based therapeutics, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development… From the company’s description.
In fiscal 2025, Repligen Corporation reported revenue of $738.26M, up 16.4% from fiscal 2024, and net income of $48.89M. Its operating margin was 7.5%, and operations generated $117.42M in cash. Over the twelve months to Jun 30, 2026, revenue was $785.10M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Repligen Corporation does
In the company’s own words
Repligen Corporation (Nasdaq: RGEN) develops and commercializes technologies and systems used to manufacture biological drugs, including monoclonal antibodies, recombinant proteins, RNA-based therapeutics, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, other life sciences companies, diagnostics companies, and laboratory researchers. Repligen operates as one bioprocessing business, organized around four product franchises: Filtration, including fluid management; Chromatography; Process Analytics, branded PATsmart; and Proteins. Its products support upstream and downstream manufacturing, from cell retention and filtration to purification, process monitoring, affinity ligands, resins, and growth factors. Much of its revenue comes from consumable and single-use products, alongside hardware and equipment. Major product brands include XCell, TangenX, KrosFlo, OPUS, SoloVPE, FlowVPX, and AVIPure. The company has built its portfolio through internal development and acquisitions, completing 15 acquisitions across its franchises since 2012. In fiscal 2025, Repligen employed approximately 2,000 people and operated 19 manufacturing sites. Its website is www.repligen.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- WALTHAM, MA
- Fiscal year end
- December
- CIK
- 730272
- SIC
- 2836
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Repligen Corporation — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Superinvestors in Repligen Corporation · what they did last quarter
Share of each manager’s reported 13F portfolio. Change is in shares held, since the previous quarter.
Largest fund holders · Repligen Corporation’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Repligen Corporation’s bonds, as funds hold them
Funds report holding 1 issues of Repligen Corporation’s debt, $96.31M at market value — what funds hold, not the company’s total debt. Weighted-average coupon 1.00%, maturing 2028 to 2028.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Repligen Corporation and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Repligen Corporation's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Repligen Corporation's last four quarterly filings that the numbers alone won't show?”